These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38780204)

  • 1. Buffer effects on protein sieving losses in ultrafiltration and their relationship to biophysical properties.
    Mohammadzadehmarandi A; Zydney AL
    Biotechnol Prog; 2024 May; ():e3481. PubMed ID: 38780204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Histidine and Sucrose on the Biophysical Properties of a Monoclonal Antibody.
    Baek Y; Singh N; Arunkumar A; Zydney AL
    Pharm Res; 2017 Mar; 34(3):629-639. PubMed ID: 28035628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of protein and solution properties on the Donnan effect during the ultrafiltration of proteins.
    Bolton GR; Boesch AW; Basha J; Lacasse DP; Kelley BD; Acharya H
    Biotechnol Prog; 2011; 27(1):140-52. PubMed ID: 21312362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. pH variations during diafiltration due to buffer nonidealities.
    Baek Y; Yang D; Singh N; Arunkumar A; Ghose S; Li ZJ; Zydney AL
    Biotechnol Prog; 2017 Nov; 33(6):1555-1560. PubMed ID: 28840650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of ultrafiltration/diafiltration for the processing of antisense oligonucleotides.
    Gronke RS; Ruanjaikaen K; Delavari A; Immel-Brown JP; Penrod JC; Lam Y; Antia FD
    Biotechnol Prog; 2023; 39(4):e3350. PubMed ID: 37186510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Small-Scale Process for Predicting Donnan and Volume Exclusion Effects During Ultrafiltration/Diafiltration Process Development.
    Abel J; Kosky A; Ball N; Bacon H; Kaushik R; Kleemann GR
    J Pharm Sci; 2018 May; 107(5):1296-1303. PubMed ID: 29339134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basal buffer systems for a newly glycosylated recombinant human interferon-β with biophysical stability and DoE approaches.
    Kim NA; Song K; Lim DG; Hada S; Shin YK; Shin S; Jeong SH
    Eur J Pharm Sci; 2015 Oct; 78():177-89. PubMed ID: 26215462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theoretical analysis of excipient concentrations during the final ultrafiltration/diafiltration step of therapeutic antibody.
    Miao F; Velayudhan A; DiBella E; Shervin J; Felo M; Teeters M; Alred P
    Biotechnol Prog; 2009; 25(4):964-72. PubMed ID: 19569193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting diafiltration solution compositions for final ultrafiltration/diafiltration steps of monoclonal antibodies.
    Teeters M; Bezila D; Benner T; Alfonso P; Alred P
    Biotechnol Bioeng; 2011 Jun; 108(6):1338-46. PubMed ID: 21328314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of protein fouling during ultrafiltration using a two-layer membrane model.
    Boyd RF; Zydney AL
    Biotechnol Bioeng; 1998 Aug; 59(4):451-60. PubMed ID: 10099359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Impurities from Sugar Excipient on Filtrate Flux during Ultrafiltration and Diafiltration Process.
    Lee J; Na J; Baek Y
    Membranes (Basel); 2021 Oct; 11(10):. PubMed ID: 34677543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule clearance in ultrafiltration/diafiltration in relation to protein interactions:Study of citrate binding to a Fab.
    Harinarayan C; Skidmore K; Kao Y; Zydney AL; van Reis R
    Biotechnol Bioeng; 2009 Apr; 102(6):1718-22. PubMed ID: 19132743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nano Differential Scanning Fluorimetry-Based Thermal Stability Screening and Optimal Buffer Selection for Immunoglobulin G.
    Kim SH; Yoo HJ; Park EJ; Na DH
    Pharmaceuticals (Basel); 2021 Dec; 15(1):. PubMed ID: 35056086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of ultrafiltration/diafiltration processes for partially bound impurities.
    Shao J; Zydney AL
    Biotechnol Bioeng; 2004 Aug; 87(3):286-92. PubMed ID: 15281103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein-solute interactions affect the outcome of ultrafiltration/diafiltration operations.
    Stoner MR; Fischer N; Nixon L; Buckel S; Benke M; Austin F; Randolph TW; Kendrick BS
    J Pharm Sci; 2004 Sep; 93(9):2332-42. PubMed ID: 15295793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A mechanistic model to account for the Donnan and volume exclusion effects in ultrafiltration/diafiltration process of protein formulations.
    Yu Z; Moomaw JF; Thyagarajapuram NR; Geng SB; Bent CJ; Tang Y
    Biotechnol Prog; 2021 Mar; 37(2):e3106. PubMed ID: 33289341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultrafiltration of highly concentrated antibody solutions: Experiments and modeling for the effects of module and buffer conditions.
    Binabaji E; Ma J; Rao S; Zydney AL
    Biotechnol Prog; 2016 May; 32(3):692-701. PubMed ID: 26918655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fundamental analysis of recombinant human epidermal growth factor in solution with biophysical methods.
    Kim NA; Lim DG; Lim JY; Kim KH; Jeong SH
    Drug Dev Ind Pharm; 2015 Feb; 41(2):300-6. PubMed ID: 24502269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of diafiltration sieving behavior of lysozyme-BSA mixtures with osmotic second virial cross-coefficients.
    Tessier PM; Verruto VJ; Sandler SI; Lenhoff AM
    Biotechnol Bioeng; 2004 Aug; 87(3):303-10. PubMed ID: 15281105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Countercurrent staged diafiltration for formulation of high value proteins.
    Nambiar AMK; Li Y; Zydney AL
    Biotechnol Bioeng; 2018 Jan; 115(1):139-144. PubMed ID: 28865125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.